Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 9/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.55 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | ECE1 | P42892 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | PRNP | P04156 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13788340 | 0.79 | RAB9A (0.50) | ADORA2AADORA1ADORA3ADORA2BRAB9A | |
| SCHEMBL13594796 | 0.78 | ADORA2A (0.45) | ADORA2AADORA1ADORA3ADORA2BRAB9A | |
| SCHEMBL13595039 | 0.75 | RAB9A (0.46) | ADORA2AADORA1ADORA3ADORA2BRAB9A | |
| SCHEMBL8006456 | 0.74 | RPS6KB2 (0.53) | ADORA2ARAB9A | |
| SCHEMBL24926667 | 0.73 | ADORA2A (0.47) | ADORA2AADORA1ADORA3ADORA2BPDPK1 | |
| SCHEMBL12676689 | 0.73 | ADORA2A (0.49) | ADORA2AADORA1ADORA3ADORA2BRAB9A | |
| SCHEMBL13787413 | 0.72 | KDM4E (0.54) | RAB9ATGFBR1POLB | |
| SCHEMBL12669829 | 0.72 | ADORA2A (0.45) | ADORA2AADORA1ADORA3ADORA2BRAB9A | |
| SCHEMBL13150847 | 0.71 | MAPT (0.53) | RAB9APOLB | |
| SCHEMBL1754983 | 0.71 | ADORA2A (1.00) | ADORA2AADORA1ADORA3ADORA2BRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962551-B2 | Quinoxalinyl derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20090180981-A1 | QUINOXALINYL DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-07-16 | — | — | US | disclosed |
| US-20090180981-A1 | QUINOXALINYL DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-07-16 | — | — | US | disclosed |
| WO-2009073719-A1 | QUINOXALINYL DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090180981-A1 | QUINOXALINYL DERIVATIVES | SQOR, ATG4A, NQO1 | ADORA2A 2627/4885ADORA1 3077/4885ADORA3 2847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.